Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...
Kintor Completes Enrollment for GT20029 Phase I Study in US
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...
Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial
Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...
WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan
China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...
Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...
CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...
Merck’s Q3 Sales Rise on Key Drug Performances, China Growth
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...
Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...
Shanghai Launches Inhaled COVID-19 Vaccine Booster Program
On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...
Ocumension Initiates Second Phase III Denali Study for OT-301 in US
China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...
Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma
The College of Pharmacy at Nankai University has established a postgraduate practice base at the...
Yiming and WZ Biosciences Collaborate on mRNA Process Platform
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...
BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...
Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...
JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform
China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...
Ascletis Pharma Files IND for Monkeypox Antiviral ASC10 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...
Simcere Receives FDA Clearance for Clinical Study of SIM0237
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...
Ping An Life Insurance Reports Q3 Results, Advances Healthcare Strategy
Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...